2020-04-02
Pavel Kapysh / Shutterstock.com
22 June 2021Big PharmaMuireann Bolger

SCOTUS won’t resuscitate Amarin’s Vascepa patents

Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa (icosapent ethyl), allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More on this story

Big Pharma
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More on this story

Big Pharma
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.